Literature DB >> 12744888

Three types of immunotherapics against pythiosis insidiosi developed and evaluated.

J M Santurio1, A T Leal, A B M Leal, R Festugatto, I Lubeck, E S V Sallis, M V Copetti, S H Alves, L Ferreiro.   

Abstract

Pythiosis is a granulomatous disease of horses, cattle, dogs, cats and humans identified in tropical and subtropical areas and caused by Pythium insidiosum, a zoosporic fungus. Experimental models of pythiosis in naturally infected species have not yet been reported but, rabbits may be inoculated with zoospores as an experimental model for studying the disease. The present study evaluates the efficacy of three different of immunotherapics in the rabbit model. Approximately 17500 zoospores of oomycete P. insidiosum (CBS 101555 strain) were inoculated in each animal to generate the disease. Immunotherapics were produced from vortexed or sonicated cultures of the same strain. Four groups of five animals were employed: group 1, placebo; group 2, sonicated immunotherapic; group 3, mixed immunotherapic; and group 4, vortexed immunotherapic. All rabbits were inoculated with viable zoospores one month before administration of the immunotherapics. Eight doses of immunotherapic or placebo were used in each animal with a 14 day interval between injections. Rabbits receiving the vortexed immunotherapic were most effectively protected (P<0.05), showing a decrease in the area of coastal nodules due to Pythiosis insidiosum by 71.8% after 26 weeks of evaluation. Moreover, two animals in this group showed complete remission of the infection at the end of the 26 weeks. In contrast to these findings, rabbits given the sonicated immunotherapic did not show any protection and had an increase of 211.8% in the size of lesions. This failure of sonicated immunotherapic may reflect denaturation of protective antigens due to the sonication method.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744888     DOI: 10.1016/s0264-410x(03)00035-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Identification of Pythium insidiosum by nested PCR in cutaneous lesions of Brazilian horses and rabbits.

Authors:  Sonia A Botton; Daniela I B Pereira; Mateus M Costa; Maria Isabel Azevedo; Juliana S Argenta; Francielli P K Jesus; Sydney Hartz Alves; Janio Morais Santurio
Journal:  Curr Microbiol       Date:  2010-12-25       Impact factor: 2.188

2.  In vitro activities of voriconazole, itraconazole, and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil.

Authors:  Juliana S Argenta; Janio M Santurio; Sydney H Alves; Daniela I B Pereira; Ayrton S Cavalheiro; Andréia Spanamberg; Laerte Ferreiro
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

3.  In vitro susceptibility of Pythium insidiosum isolates to aminoglycoside antibiotics and tigecycline.

Authors:  Deise Luiza Mahl; Francielli Pantella Kunz de Jesus; Érico Silva Loreto; Régis Adriel Zanette; Laerte Ferreiro; Maiara Ben Pilotto; Sydney Hartz Alves; Janio Morais Santurio
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

4.  The 74-kilodalton immunodominant antigen of the pathogenic oomycete Pythium insidiosum is a putative exo-1,3-beta-glucanase.

Authors:  Theerapong Krajaejun; Angsana Keeratijarut; Kanchana Sriwanichrak; Tassanee Lowhnoo; Thidarat Rujirawat; Thanom Petchthong; Wanta Yingyong; Thareerat Kalambaheti; Nat Smittipat; Tada Juthayothin; Thomas D Sullivan
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

5.  Does immunotherapy protect equines from reinfection by the oomycete Pythium insidiosum?

Authors:  Carlos E P Santos; Luiz C Marques; Régis A Zanette; Francielli P K Jesus; Janio M Santurio
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

6.  In vitro susceptibility of Pythium insidiosum to macrolides and tetracycline antibiotics.

Authors:  Erico Silva Loreto; Débora Alves Nunes Mario; Laura Bedin Denardi; Sydney Hartz Alves; Janio Morais Santurio
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

7.  Identification of a novel 74-kiloDalton immunodominant antigen of Pythium insidiosum recognized by sera from human patients with pythiosis.

Authors:  Theerapong Krajaejun; Mongkol Kunakorn; Rungnapa Pracharktam; Piriyaporn Chongtrakool; Boonmee Sathapatayavongs; Angkana Chaiprasert; Nongnuch Vanittanakom; Ariya Chindamporn; Piroon Mootsikapun
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 8.  Canine gastrointestinal pythiosis treatment by combined antifungal and immunotherapy and review of published studies.

Authors:  Daniela I B Pereira; Sônia A Botton; Maria I Azevedo; Marco A A Motta; Raulene R Lobo; Mauro P Soares; Anelise O S Fonseca; Francielli P K Jesus; Sydney H Alves; Janio M Santurio
Journal:  Mycopathologia       Date:  2013-08-07       Impact factor: 2.574

9.  Antibodies in the sera of host species with pythiosis recognize a variety of unique immunogens in geographically divergent Pythium insidiosum strains.

Authors:  Ariya Chindamporn; Raquel Vilela; Kathleen A Hoag; Leonel Mendoza
Journal:  Clin Vaccine Immunol       Date:  2008-12-30

10.  In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum.

Authors:  Francielli P K Jesus; Érico S Loreto; Laerte Ferreiro; Sydney H Alves; David Driemeier; Suyene O Souza; Raqueli T França; Sonia T A Lopes; Maiara B Pilotto; Aline Ludwig; Maria I Azevedo; Tatiana C Ribeiro; Juliana S M Tondolo; Janio M Santurio
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.